AMA Statement on updated COVID-19 boosters

Translate to Spanish or other 102 languages!

“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses."  Image for illustration purposes
“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses.” Image for illustration purposes

Mega Doctor News

- Advertisement -
Sandra Adamson Fryhofer, M.D.
Image Source: ama-assn.org

The following statement is attributable to:
Sandra Adamson Fryhofer, M.D.
Board Chair, American Medical Association

“Given that the BA.5 Omicron subvariant is responsible for the majority of COVID-19 infections currently circulating throughout the U.S., we welcome today’s recommendations by the Advisory Committee on Immunization Practices (ACIP) supporting a bivalent booster dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines—targeting the BA.4/BA.5 Omicron subvariants as well as the original variant. ACIP’s recommendations, following the U.S. Food and Drug Administration’s (FDA) authorization on Wednesday, will allow individuals 12 years and older to receive a booster dose of Pfizer’s bivalent vaccine and anyone 18 years and older to receive a booster dose of Moderna’s bivalent vaccine at least two months after completing their primary vaccine series or their most recent booster. The bivalent booster recommendation replaces previous booster recommendations with a monovalent booster dose for people ages 12 years and older.

“With COVID-19 infections continuing to impact the U.S. population and an increase in infections expected this fall and winter, data shows that the updated bivalent vaccines will increase immune response and help provide protection against severe COVID-19 outcomes including hospitalization and death. Vaccine effectiveness against SARS-CoV-2 infection wanes over time and vaccine booster doses have been shown to increase protection. With the highly transmissible Omicron variant continuing to evolve, broad update of a bivalent booster dose will help provide an additional layer of protection and could prevent more than 100,000 hospitalizations compared to a later roll-out.”

- Advertisement -

“We continue to strongly urge everyone to stay up to date on their COVID-19 vaccines, including recommended booster doses, to protect themselves and their loved ones from severe complications, hospitalization, and death. Anyone with questions about the vaccines should speak with their physician and review trusted resources, including getvaccineanswers.org.”

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

AACT NOW to Launch Rally the Vote Across Rio Grande Valley

The Advocacy Alliance Center of Texas, known as AACT NOW, will officially launch its Rally the Vote initiative Thursday, Oct. 1, bringing together community partners working to expand access to accurate, nonpartisan election information across the Rio Grande Valley.

DHR Health Offers Mammogram Screening Special During “Breast Cancer Awareness Month”

October is “Breast Cancer Awareness Month,” and DHR Health is encouraging women to prioritize their breast health by offering their annual mammogram screening special.

FDA Approves First Treatment for MCT8 Deficiency

The U.S. Food and Drug Administration approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes symptoms, such as rapid heart rate, increased blood pressure and adverse effects on metabolism) in patients with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.

DHR Health Enhances Ear, Nose, and Throat Care with Addition of Dr. Tess Hill

As part of its ongoing commitment to expanding access to outstanding healthcare throughout the Rio Grande Valley, DHR Health is pleased to welcome Dr. Tess Hill to its growing team of physicians. Dr. Hill joins DHR Health as an otolaryngologist (ear, nose and throat physician) and looks forward to providing compassionate, patient-centered care.
- Advertisement -